• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

移植后淋巴组织增生性疾病后的造血干细胞移植。

Hematopoietic stem cell transplantation after posttransplant lymphoproliferative disorder.

机构信息

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

出版信息

J Korean Med Sci. 2010 May;25(5):781-4. doi: 10.3346/jkms.2010.25.5.781. Epub 2010 Apr 16.

DOI:10.3346/jkms.2010.25.5.781
PMID:20436718
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2858841/
Abstract

A 16-yr-old girl received liver transplantation for fulminant hepatitis. Aplastic anemia developed, and she received hematopoietic stem cell transplantation (HSCT). Eleven months after liver transplantation, abdominal lymph node enlargement and colon ulcers were observed, and colon biopsy showed posttransplant lymphoproliferative disorder (PTLD). Immunosuppression reduction was attempted, but it produced no therapeutic effect. Fourteen months after liver transplantation, she received a second HSCT due to engraftment failure, and PTLD resolved completely. The second HSCT can serve as cellular therapy for PTLD.

摘要

一名 16 岁女孩因暴发性肝炎接受了肝脏移植。后来她发生再生障碍性贫血，并接受了造血干细胞移植（HSCT）。肝脏移植 11 个月后，她出现腹部淋巴结肿大和结肠溃疡，结肠活检显示移植后淋巴组织增生性疾病（PTLD）。尝试减少免疫抑制，但没有产生治疗效果。肝脏移植 14 个月后，由于植入失败，她接受了第二次 HSCT，PTLD 完全缓解。第二次 HSCT 可以作为 PTLD 的细胞治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3284/2858841/4f5d0759b483/jkms-25-781-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3284/2858841/b04f13dc2f1f/jkms-25-781-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3284/2858841/92fcda9dc33a/jkms-25-781-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3284/2858841/b13d5c8c0c3f/jkms-25-781-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3284/2858841/82f0c035f1ff/jkms-25-781-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3284/2858841/41aed8daffcb/jkms-25-781-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3284/2858841/4f5d0759b483/jkms-25-781-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3284/2858841/b04f13dc2f1f/jkms-25-781-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3284/2858841/92fcda9dc33a/jkms-25-781-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3284/2858841/b13d5c8c0c3f/jkms-25-781-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3284/2858841/82f0c035f1ff/jkms-25-781-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3284/2858841/41aed8daffcb/jkms-25-781-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3284/2858841/4f5d0759b483/jkms-25-781-g006.jpg

相似文献

1
Hematopoietic stem cell transplantation after posttransplant lymphoproliferative disorder.移植后淋巴组织增生性疾病后的造血干细胞移植。
J Korean Med Sci. 2010 May;25(5):781-4. doi: 10.3346/jkms.2010.25.5.781. Epub 2010 Apr 16.
2
Posttransplant Lymphoproliferative Disorder in Solid Organ and Hematopoietic Stem Cell Transplantation.实体器官和造血干细胞移植中的移植后淋巴组织增生性疾病。
Clin Chest Med. 2017 Dec;38(4):771-783. doi: 10.1016/j.ccm.2017.08.001. Epub 2017 Sep 21.
3
[A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation].异基因造血干细胞移植后淋巴增殖性疾病的临床研究
Zhonghua Nei Ke Za Zhi. 2007 Dec;46(12):996-9.
4
Low incidence of posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab.利妥昔单抗治疗的淋巴瘤患者异基因干细胞移植后发生移植后淋巴组织增生性疾病的发生率低。
Hematol Oncol. 2020 Apr;38(2):146-152. doi: 10.1002/hon.2714. Epub 2020 Feb 3.
5
Recipient-derived EBV-positive Monomorphic Plasmacytoma Type Posttransplant Lymphoproliferative Disorder After Allogeneic Stem Cell Transplant for Severe Aplastic Anemia: A Case Report.
J Pediatr Hematol Oncol. 2016 Nov;38(8):e310-e314. doi: 10.1097/MPH.0000000000000613.
6
Posttransplantation lymphoproliferative disorder in children: manifestations in hematopoietic cell recipients in comparison with liver recipients.儿童移植后淋巴组织增生性疾病：与肝移植受者相比，造血细胞移植受者的表现。
Radiology. 2010 Nov;257(2):490-7. doi: 10.1148/radiol.10092389. Epub 2010 Sep 9.
7
Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.儿童和成人造血干细胞移植后 EBV 相关淋巴组织增生性疾病对利妥昔单抗治疗的反应及危险因素分析：来自欧洲血液和骨髓移植学会传染病工作组的研究。
Clin Infect Dis. 2013 Sep;57(6):794-802. doi: 10.1093/cid/cit391. Epub 2013 Jun 13.
8
Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation.造血干细胞移植后发生移植后淋巴组织增生性疾病的危险因素和预测评分系统。
Biol Blood Marrow Transplant. 2019 Jul;25(7):1441-1449. doi: 10.1016/j.bbmt.2019.02.016. Epub 2019 Feb 20.
9
Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.实体器官和造血干细胞移植后的移植后淋巴组织增生性疾病。
Leuk Lymphoma. 2019 Jan;60(1):142-150. doi: 10.1080/10428194.2018.1474462. Epub 2018 Jul 3.
10
Posttransplant lymphoproliferative disorder complicating hematopoietic stem cell transplantation in a patient with dyskeratosis congenita.先天性角化不良患者造血干细胞移植后并发移植后淋巴细胞增殖性疾病
Int J Surg Pathol. 2013 Oct;21(5):520-5. doi: 10.1177/1066896912468214. Epub 2012 Dec 5.

本文引用的文献

1
Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.利妥昔单抗（嵌合抗CD20抗体）用于成人实体器官移植后移植后淋巴细胞增生性疾病：单中心长期经验
Transplantation. 2005 Dec 27;80(12):1692-8. doi: 10.1097/01.tp.0000185570.41571.df.
2
Epstein-Barr virus and lymphoproliferative disorders after transplantation.
Am J Transplant. 2004 Nov;4 Suppl 10:59-65. doi: 10.1111/j.1600-6135.2004.00728.x.
3
Posttransplant malignancy.移植后恶性肿瘤
Prog Transplant. 2004 Sep;14(3):193-200. doi: 10.1177/152692480401400304.
4
Cancer risk following organ transplantation: a nationwide cohort study in Sweden.器官移植后的癌症风险：瑞典的一项全国性队列研究。
Br J Cancer. 2003 Oct 6;89(7):1221-7. doi: 10.1038/sj.bjc.6601219.
5
Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.利妥昔单抗联合雷帕霉素用于移植后淋巴细胞增生性疾病的治疗。
Transpl Int. 2003 Mar;16(3):202-6. doi: 10.1007/s00147-002-0487-9. Epub 2003 Feb 13.
6
Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease.在部分去除T细胞的异基因干细胞移植后，爱泼斯坦-巴尔病毒（EBV）特异性CD8 + T淋巴细胞恢复受损可能提示患者发生进行性EBV再激活和淋巴增殖性疾病的风险极高。
Blood. 2003 Jun 1;101(11):4290-7. doi: 10.1182/blood-2002-10-3001. Epub 2003 Feb 6.
7
Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.采用部分人类白细胞抗原匹配的异基因细胞毒性T细胞治疗爱泼斯坦-巴尔病毒阳性移植后淋巴细胞增生性疾病。
Lancet. 2002 Aug 10;360(9331):436-42. doi: 10.1016/S0140-6736(02)09672-1.
8
Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells.使用部分 HLA 匹配的 Epstein Barr 病毒特异性细胞毒性 T 细胞使移植后淋巴细胞增生性疾病完全消退。
Transplantation. 2001 Oct 27;72(8):1399-402. doi: 10.1097/00007890-200110270-00012.
9
The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis.爱泼斯坦-巴尔病毒与移植后淋巴细胞增生性疾病：免疫抑制、爱泼斯坦-巴尔病毒及免疫系统在疾病发病机制中的相互作用
Transpl Infect Dis. 2001 Jun;3(2):60-9. doi: 10.1034/j.1399-3062.2001.003002060.x.
10
Epstein-Barr virus infection.爱泼斯坦-巴尔病毒感染
N Engl J Med. 2000 Aug 17;343(7):481-92. doi: 10.1056/NEJM200008173430707.